{"id":"NCT00981045","sponsor":"American Regent, Inc.","briefTitle":"Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function","officialTitle":"Randomized Evaluation of Efficacy and Safety of Ferric Carboxymaltose in Patients With Iron Deficiency Anemia and Impaired Renal Function","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08","primaryCompletion":"2011-07","completion":"2011-08","firstPosted":"2009-09-22","resultsPosted":"2013-10-18","lastUpdate":"2018-02-20"},"enrollment":2561,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Iron Deficiency Anemia","Impaired Renal Function"],"interventions":[{"type":"DRUG","name":"Ferric Carboxymaltose (FCM)","otherNames":[]},{"type":"DRUG","name":"Iron Sucrose (Venofer)","otherNames":[]}],"arms":[{"label":"Ferric Carboxymaltose (FCM)","type":"EXPERIMENTAL"},{"label":"Iron Sucrose (Venofer)","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of this study is to examine the efficacy and safety (cardiovascular) of an investigational intravenous (IV) iron, ferric carboxymaltose (FCM), compared to IV iron sucrose (Venofer) in subjects who have iron deficiency anemia (IDA) and impaired renal function.","primaryOutcome":{"measure":"Mean Change From Baseline to the Highest Observed Hemoglobin Any Time From Baseline to End of Study.","timeFrame":"Day 56","effectByArm":[{"arm":"Ferric Carboxymaltose (FCM)","deltaMin":1.13,"sd":1.044},{"arm":"Iron Sucrose (Venofer)","deltaMin":0.92,"sd":0.917}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":13},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":202,"n":1276},"commonTop":["Hypertension","Nausea"]}}